Nicotine pouches are increasingly caught between two competing public-health narratives. One presents them as smoke-free alternatives that could reduce harm among adults who would otherwise continue smoking. The other focuses on their potential to introduce nicotine to young people and people who have never used nicotine.
A new pharmacy-focused review accepted by the Journal of the American Pharmacists Association on 23 August 2026 suggests that these two possibilities should not be treated as mutually exclusive. After reviewing evidence across pharmacology, toxicology, smoking behaviour, youth use and product safety, the authors conclude that nicotine pouches occupy a “dual position”: they may offer harm-reduction potential for adults who smoke, particularly through complete switching, while creating different concerns when used by young people and nicotine-naïve individuals.
This distinction has implications beyond pharmacy practice. It reinforces a broader regulatory principle: the public-health impact of a nicotine product depends not simply on the product itself, but on who uses it, how it is used and what behaviour it replaces.
A Review of a Rapidly Developing Evidence Base
The researchers conducted a structured narrative evidence synthesis covering literature published between January 2019 and April 2026. Searches of PubMed, Web of Science and Google Scholar initially identified 214 records. Following screening, 35 peer-reviewed studies were included, alongside 15 foundational references covering nicotine pharmacology, tobacco harm reduction and pharmacy practice.
This was not a systematic review or meta-analysis. The authors explain that the evidence base includes substantially different study designs and outcomes, ranging from chemical analyses and pharmacokinetic trials to biomarker studies, population surveys and marketing research. Their conclusions should therefore be understood as a synthesis of an evolving literature rather than a quantitative estimate of the overall benefits and risks of nicotine pouches.
That limitation is important, but so is the breadth of the review. By considering evidence on both adult substitution and youth initiation, the paper avoids reducing the debate to a choice between two opposing narratives.
Removing Combustion Changes the Risk Question
The strongest case for nicotine pouches as a harm-reduction product comes from what they remove: combustion.
Cigarette smoking generates carbon monoxide and numerous harmful compounds through burning tobacco. Nicotine pouches deliver nicotine through the oral mucosa without smoke or combustion. The review found that biomarker studies generally show lower exposure to several harmful constituents among people using nicotine pouches compared with people who continue smoking.
The paper’s comparison of nicotine delivery systems places combustible cigarettes at the highest end of its toxicant continuum, with nicotine replacement therapies and nicotine pouches toward the lower end. However, the authors also stress that long-term clinical outcome data for nicotine pouches remain unavailable.
This distinction matters. Reduced exposure to harmful constituents is relevant evidence, but it should not automatically be translated into precise estimates of long-term disease reduction. Biomarkers are intermediate measures. Longer-term evidence will be needed to determine the implications for cardiovascular disease, cancer and other clinical outcomes.
Nicotine Delivery Is More Complex Than the Number on the Pouch
The review also highlights substantial variation between nicotine pouch products.
Studies cited by the authors found differences in nicotine content, pH and the proportion of free nicotine available for absorption. Pharmacokinetic research indicates that pouches generally deliver nicotine more slowly than cigarettes. In one study discussed in the review, time to maximum nicotine concentration was approximately 60–65 minutes for nicotine pouches compared with seven minutes for cigarettes. Higher-strength pouches, however, were capable of producing nicotine exposure similar to or greater than a cigarette.
This has important implications for product standards. Nicotine content alone does not provide a complete picture of nicotine delivery. Product formulation, pH, free nicotine and absorption characteristics can all affect exposure.
For regulators considering nicotine limits, the evidence supports looking beyond a simple milligram threshold. Standards should be informed by how products actually deliver nicotine and how those characteristics influence dependence, substitution and unintended use.
Harm Reduction Depends on What the Product Replaces
Perhaps the most important qualification in the review concerns complete switching.
For an adult who would otherwise continue smoking, replacing cigarettes completely with a non-combustible product may substantially reduce exposure to combustion-related toxicants. The same benefit cannot automatically be assumed when nicotine pouches are simply added to continued cigarette use.
The authors identify dual and poly-nicotine use as an important concern. If a person uses pouches while continuing to smoke, exposure to cigarette smoke remains. This means that evaluating nicotine pouches solely by the number of people who have tried them can obscure the outcome that matters most for harm reduction: whether they displace combustible cigarettes.
This is an important distinction for both research and regulation. The relevant question is not simply whether adults use nicotine pouches. Policymakers also need to understand whether use results in complete switching, prolonged dual use, temporary experimentation or eventual nicotine cessation.
Harm Reduction Is Not the Same as Smoking-Cessation Treatment
The review makes another distinction that can easily become blurred in public discussion: a product can potentially reduce harm without being an approved smoking-cessation medicine.
The authors found that nicotine pouches have not demonstrated statistically significant smoking-cessation efficacy in the randomized trials covered by the review. They therefore stress that nicotine pouches should not be presented as equivalent to FDA-approved nicotine replacement therapies such as gum, lozenges and patches.
This does not negate evidence showing lower toxicant exposure when cigarettes are replaced by pouches. The two claims answer different questions.
Smoking-cessation efficacy asks whether an intervention has been demonstrated to help people stop smoking under defined clinical endpoints. Harm reduction asks whether replacing a more hazardous behaviour with a lower-exposure alternative can reduce harm.
Keeping those concepts separate can improve both clinical advice and public communication.
Youth Use Requires a Different Public-Health Response
The potential benefit for adults who smoke does not remove concerns about nicotine uptake among young people.
The review points to evidence of growing awareness and experimentation among adolescents. U.S. Monitoring the Future data cited by the authors showed past-30-day nicotine pouch use among 10th- and 12th-grade students increasing from 1.3% in 2023 to 2.6% in 2024. Research across Canada, England, the United States and New Zealand has also documented increasing awareness and use among youth and young adults.
At the same time, much of the available youth evidence is cross-sectional. It can identify patterns and associations, but it cannot establish whether nicotine pouches cause nicotine-naïve young people to progress to sustained nicotine use or subsequently to smoking.
That uncertainty should not be interpreted as a reason for inaction. Age restrictions, responsible marketing rules, effective age verification and continued surveillance are appropriate safeguards. It does mean that claims about a definitive “gateway” pathway should reflect the current limits of longitudinal evidence.
Product Safety Extends Beyond Intended Use
Another important part of the review concerns accidental exposure among children.
The authors cite U.S. poison-centre research showing a sharp increase in reported nicotine pouch ingestions among children younger than six between 2020 and 2023. The same research found higher odds of serious medical outcomes and hospital admission following pouch exposure compared with other nicotine-product exposures.
This provides a particularly strong case for product standards that do not depend on assumptions about adult consumer behaviour. Child-resistant packaging, clear nicotine labelling, appropriate storage warnings and controls around very high-strength products can reduce preventable risks while allowing regulators to address adult use separately.
This is where product standards can play an important role. A risk-proportionate framework does not mean lighter regulation in every area. It means matching regulatory requirements to the risks that need to be addressed.
The Evidence Still Has Significant Gaps
The review is careful about the limitations of the current evidence. Much of the harm-reduction literature relies on short-term biomarkers rather than long-term clinical outcomes. Several pharmacokinetic and biomarker studies have industry funding or affiliations, making independent replication particularly valuable. Evidence on sustained complete switching remains limited, while long-term cardiovascular and other health outcomes require further investigation.
There are comparable gaps on the initiation side. Cross-sectional surveys can show that youth use exists and is changing, but longitudinal studies following nicotine-naïve adolescents are needed to understand whether experimentation progresses to regular use, dependence or use of other nicotine products.
The authors also note that much of the evidence comes from North America and Europe. As nicotine pouches enter additional markets, surveillance and research will need to account for very different smoking patterns, regulatory environments and consumer behaviours.
The review itself has limitations too. It is a structured narrative synthesis rather than a formal systematic review or meta-analysis. The paper is currently a journal pre-proof and may undergo further copyediting before publication as the final Version of Record. The authors report NIH grant support and declare no relevant conflicts of interest or financial relationships.
Moving Beyond a Binary Debate
The most useful contribution of this review may be its rejection of a simple answer to the question posed in its title.
Nicotine pouches can plausibly have different public-health consequences in different populations. For an adult who smokes and switches completely, the relevant comparison is continued exposure to combustible cigarette smoke. For a young person who has never used nicotine, there is no smoking-related exposure to reduce, and preventing initiation is the appropriate objective.
Those situations should not be regulated as though they are identical.
For GINN, this points toward a framework that combines strong youth protections with proportionate regulation for adult consumers. That includes meaningful age verification, responsible marketing standards, child-resistant packaging, appropriate nicotine and product-quality standards, transparent consumer information, and continued surveillance of both switching and initiation.
It also requires better evidence. Long-term independent studies should examine complete switching, dual use, sustained dependence and health outcomes. Youth research should distinguish experimentation from regular use and establish temporal pathways rather than relying primarily on cross-sectional associations.
The policy debate around nicotine pouches is often framed as a choice: harm reduction or initiation risk. The emerging evidence suggests that this may be the wrong question.
A more useful question is for whom, under what circumstances, and compared with what?
Regulation that begins with those distinctions is more likely to protect young people while preserving the potential public-health value of moving adults away from combustible cigarettes.
Source
Souza EF, Parang K. Nicotine pouches: Harm reduction or initiation pathway? A pharmacy-focused review. Journal of the American Pharmacists Association. Accepted 23 August 2026. DOI: 10.1016/j.japh.2026.103517.
